α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 993-998

  Zhuo, Ren Jie ^a   Wang, Feng ^b   Zhang, Xiao Hong ^a   Zhang, Jin Jie ^a   Xu, Jin ^a   Dong, Wei ^a   Zou, Zu Quan ^a  

^a NINGBO UNIVERSITY   (China)

^b Lihui Li Hospital   (China)

Author keywords

ESA; Breast cancer; HER 2; HER 3

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LINOLENIC ACIDS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84893841605     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1892     Document Type: Article

References (25)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
2. Yu D and Hung MC: Role of erbB2 in breast cancer chemosensitivity. Bioessays 22: 673-680, 2000.
3. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
4. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
5. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639, 2006.
6. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GV and Bacus SS: The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91: 1190-1194, 2004.
7. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441, 2007.
8. Ray RB, Raychoudhuri A, Steele R and Nerurkar P: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 70: 1925-1931, 2010.
9. Grossmann ME, Mizuno NK, Dammen ML, Schuster T, Ray A and Cleary MP: Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prev Res (Phila) 2: 879-886, 2009.
10. Moon HS, Guo DD, Lee HG, Choi YJ, Kang JS, Jo K, Eom JM, Yun CH and Cho CS: Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2. Cancer Sci 101: 396-402, 2010.
11. Zhang T, Gao Y, Mao Y, Zhang Q, Lin C, Lin P, Zhang J and Wang X: Growth inhibition and apoptotic effect of alpha-eleostearic acid on human breast cancer cells. J Nat Med 66: 77-84, 2012.
12. Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-κB in development and progression of human cancer. Virchows Arch 446: 475-482, 2005.
13. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
14. Dhillon S: Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs 73: 475-485, 2013.
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
16. Brennan SF, Cantwell MM, Cardwell CR, Velentzis LS and Woodside JV: Dietary patterns and breast cancer risk: a systematic review and meta-analysis. Am J Clin Nutr 91: 1294-1302, 2010.
17. Montales MT, Rahal OM, Kang J, Rogers TJ, Prior RL, Wu X and Simmen RC: Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis 33: 652-660, 2012.
18. Tsuzuki T, Tokuyama Y, Igarashi M, Nakagawa K, Ohsaki Y, Komai M and Miyazawa T: α-eleostearic acid (9Z11E13E-18:3) is quickly converted to conjugated linoleic acid (9Z11E-18: ) in rats. J Nutr 134: 2634-2639, 2004.
19. Ru P, Steele R, Nerurkar PV, Phillips N and Ray RB: Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res 4: 2122-2130, 2011.
20. Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280, 2006.
21. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL and Cook RS: HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 72: 2672-2682, 2012.
22. Menendez JA, Vazquez-Martin A, Ropero S, Colomer R, Lupu R and Trueta J: HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18: 3n-3) in breast cancer cells: the 'fat features' of the 'Mediterranean diet' as an 'anti-HER2 cocktail'. Clin Trans Oncol 8: 812-820, 2006.
23. Carracedo A and Pandolfi PP: The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527-5541, 2008.
24. Eom JM, Seo MJ, Baek JY, Chu H, Han SH, Min TS, Cho CS and Yun CH: Alpha-eleostearic acid induces autophagy-dependent cell death through targeting AKT/mTOR and ERK1/2 signal together with the generation of reactive oxygen species. Biochem Biophys Res Commun 391: 903-908, 2010.
25. Draczynska-Lusiak B, Chen YM and Sun AY: Oxidized lipoproteins activate NF-kappaB binding activity and apoptosis in PC12 cells. Neuroreport 9: 527-532, 1998.